Latest News and Press Releases

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects,...

Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD)...

– Live webcast fireside chat on Tuesday, October 15th at 4:30 PM ET Carlsbad, CA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the...

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA)...

– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases – Successful completion of...

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program...

Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing...

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Company continues to...